FIELD: protein engineering, biotechnology and medicine.
SUBSTANCE: invention relates to the field of protein engineering, biotechnology and medicine. Described is a recombinant protein having the sequence of SEQ ID NO: 2 or SEQ ID NO: 9, which binds to the receptor-binding domain of the S-protein of SARS-CoV-2, as well as its use as an agent with the ability to bind to the receptor-binding domain of S -SARS-CoV-2 protein. A recombinant plasmid is disclosed that provides the synthesis of the specified recombinant protein in Escherichia coli cells, and the specified plasmid was obtained by cloning a DNA fragment with the nucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 1 into the pET39b plasmid vector at the NdeI/XhoI restriction sites. A recombinant strain of Escherichia coli BL21(DE3) containing the indicated recombinant plasmid, the producer of the described recombinant protein, is presented. In addition, a method is presented for obtaining the described recombinant protein from the biomass of the indicated recombinant Escherichia coli BL21(DE3) strain, in which cells are destroyed by disintegration, cell debris is removed, the protein is isolated using two-stage chromatography, including the stage of protein denaturation/renaturation on a metal chelate affinity sorbent, and purification by anion exchange chromatography.
EFFECT: invention can find application in biotechnology and medicine in the creation of drugs against COVID-19.
5 cl, 12 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE WITH ANTI-SARS-COV-2 ACTIVITY AND PROLONGED CIRCULATION TIME IN BLOOD FLOW | 2023 |
|
RU2822355C1 |
| RECOMBINANT PLASMID PROVIDING SYNTHESIS OF BARNASE IN CELLS OF ESCHERICHIA COLI, ESCHERICHIA COLI STRAIN - PRODUCER OF BARNASE AND METHOD FOR PRODUCING BARNASE | 2017 |
|
RU2650871C1 |
| METHOD OF PRODUCING RECOMBINANT ANTI-TUMOR TOXIN BASED ON PROTEIN BARNASE-BARSTAR AND TARGETED POLYPEPTIDE DARPIN WITH EFFECT OF INSTANT CANCELLATION OF CYTOTOXIC ACTION | 2015 |
|
RU2610179C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| PLASMID GENETIC CONSTRUCT pET21_AB_CoV-2_1.3, WHICH ENSURES THE EXPRESSION OF RECOMBINANT PROTEIN AB_CoV-2_1.3 IN THE PROKARYOTIC SYSTEM OF E. COLI, AND RECOMBINANT PROTEIN AB_CoV-2_1.3, WHICH HAS THE PROPERTIES OF A SINGLE-DOMAIN NANOANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2798508C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| ARTIFICIAL GENETIC CONSTRUCT FOR THE HETEROLOGOUS EXPRESSION OF THE S-PROTEIN RECEPTOR-BINDING DOMAIN IN A FUSED POLYPEPTIDE CHAIN WITH A NUCLEOCAPSID PROTEIN | 2022 |
|
RU2801597C1 |
| INTEGRATIVE PLASMID VECTOR PVEAL2-S-RBD, PROVIDING THE EXPRESSION AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS IN MAMMALIAN CELLS, THE RECOMBINANT CHO-K1-RBD CELL LINE STRAIN AND THE RECOMBINANT SARS-COV-2 RBD PROTEIN PRODUCED BY THE SPECIFIED STRAIN OF THE CELL LINE CHO-K1-RBD | 2021 |
|
RU2752858C1 |
